

Robert L Ferris

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/768180/robert-l-ferris-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418 papers	24,115 citations	76 h-index	142 g-index
445 ext. papers	29,664 ext. citations	6.3 avg, IF	7.15 L-index

#	Paper	IF	Citations
418	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.. <i>Frontiers in Oncology</i> , 2022 , 12, 730785	5.3	0
417	Reply to A.S. Garden.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200063	2.2	
416	Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults.. <i>Tumour Virus Research</i> , 2022 , 200237		1
415	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , 2022 , 14, 2639	6.6	1
414	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. <i>International Journal of Radiation Biology</i> , 2021 , 97, 1121-1128	2.9	17
413	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.. <i>Nature Communications</i> , 2021 , 12, 7338	17.4	7
412	Quality of life and health-related utility after trans-oral surgery for head and neck cancers. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 250	3	
411	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , 2021 , 12, 6340	17.4	2
410	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101752	2.2	20
409	Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity. <i>Oral Oncology</i> , 2021 , 123, 105574	4.4	0
408	HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures. <i>Carcinogenesis</i> , 2021 , 42, 14-20	4.6	2
407	Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic. <i>Frontiers in Oncology</i> , 2021 , 11, 651123	5.3	
406	Perceived Financial Insecurity Impacts Healthcare Decision-Making Among Patients With Sinusitis. <i>Laryngoscope</i> , 2021 , 131, 2403-2412	3.6	1
405	CD40 Agonist Targeted to Fibroblast Activation Protein β Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4054-4065	12.9	6
404	Reply to N. Hirshoren et al and D. Chakrabarti et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1600-1601	2.2	1
403	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck 2021 , 9,		16
402	Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 1261-1265	3.6	1

401	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6010-6010	2.2	9
400	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021 , 43, 2844-2858	4.2	3
399	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
398	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial 2021 , 9,		23
397	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021 , 12, 3349	17.4	32
396	The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors. <i>Head and Neck</i> , 2021 , 43, 3062-3075	4.2	5
395	TORS Base-of-Tongue Mucosectomy in Human Papilloma Virus-Negative Carcinoma of Unknown Primary. <i>Laryngoscope</i> , 2021 , 131, 78-81	3.6	10
394	PET/CT Poorly Predicts AJCC 8th Edition Pathologic Staging in HPV-Related Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021 , 131, 1535-1541	3.6	2
393	Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model. <i>Onc Immunology</i> , 2021 , 10, 1912473	7.2	3
392	Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis. <i>Cancer</i> , 2021 , 127, 1993-2002	6.4	1
391	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. <i>Cancer</i> , 2021 , 127, 1779-1787	6.4	3
390	Characterizing postoperative physiologic swallow function following transoral robotic surgery for early stage tonsil, base of tongue, and unknown primary human papillomavirus-associated squamous cell carcinoma. <i>Head and Neck</i> , 2021 , 43, 1629-1640	4.2	2
389	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021 , 7,	14.3	9
388	Epidermal Growth Factor Receptor-Targeted Therapy for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021 , 54, 743-749	2	2
387	APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Viruses</i> , 2021 , 13,	6.2	2
386	Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2732-2733	2.2	2
385	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.. <i>JID Innovations</i> , 2021 , 1, 100045		1
384	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. <i>Cell Reports</i> , 2021 , 36, 109699	10.6	3

383	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021 , 13, eabf8495	17.5	1
382	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. <i>Scientific Reports</i> , 2020 , 10, 8031	4.9	3
381	Proposal of a timing strategy for cholesteatoma surgery during the COVID-19 pandemic. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020 , 277, 2619-2623	3.5	5
380	Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity. <i>Frontiers in Oncology</i> , 2020 , 10, 688	5.3	6
379	A new endoscopic surgical approach to the larynx, hypopharynx, and neck lymphatics: The robotic-assisted extended "Sistrunk" approach (RESA). <i>Head and Neck</i> , 2020 , 42, 2750-2756	4.2	1
378	Phase I Study of Ficlatusumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020 , 12,	6.6	10
377	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020 , 16, 1235-1243	3.6	16
376	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020 , 108, 104736	4.4	23
375	Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 83	5.3	3
374	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). <i>Head and Neck</i> , 2020 , 42, 2852-2862	4.2	13
373	Best Practice in Surgical Treatment of Malignant Head and Neck Tumors. <i>Frontiers in Oncology</i> , 2020 , 10, 140	5.3	2
372	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020 , 31, 942-950	10.3	117
371	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce 2020 , 8,		43
370	Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors. <i>Head and Neck</i> , 2020 , 42, 1332-1338	4.2	36
369	Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience. <i>Head and Neck</i> , 2020 , 42, 1310-1316	4.2	40
368	Major head and neck reconstruction during the COVID-19 pandemic: The University of Pittsburgh approach. <i>Head and Neck</i> , 2020 , 42, 1243-1247	4.2	14
367	HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1635-1652	15.9	46
366	Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6500-6500	2.2	56

365	Immunotherapeutic approaches in HNSCC 2020 , 117-142		0
364	Dose-response model for severe late laryngeal toxicity after stereotactic body radiation therapy for previously-irradiated head and neck cancer. <i>Journal of Radiosurgery and SBRT</i> , 2020 , 7, 89-94	0.4	2
363	Improving responses to immunotherapy in head and neck squamous cell carcinoma 2020 , 107-133		
362	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. <i>Cancer</i> , 2020 , 126, 37-45	6.4	6
361	The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. <i>Journal of Pathology</i> , 2020 , 250, 107-119	9.4	6
360	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. <i>Immunity</i> , 2020 , 52, 183-199.	9.3	152
359	Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers. <i>Oral Oncology</i> , 2020 , 100, 104475	4.4	11
358	Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3983-3986	2.2	10
357	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. <i>Oral Oncology</i> , 2020 , 110, 104797	4.4	13
356	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020 , 5,	2.8	10
355	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. <i>Head and Neck</i> , 2020 , 42, 3141-3152	4.2	12
354	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee 2020 , 8,		6
353	Reconstruction of TORS oropharyngectomy defects with the nasoseptal flap via transpalatal tunnel. <i>Journal of Robotic Surgery</i> , 2020 , 14, 311-316	2.9	4
352	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2476-2487	2.2	72
351	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. <i>Immunity</i> , 2019 , 51, 548-560.e4	32.3	56
350	Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2019 , 9, e473-e481	2.8	14
349	A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. <i>Oral Oncology</i> , 2019 , 98, 69-77	4.4	20
348	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45

347	Response to Letter to the Editor regarding follow-up for NIFTP. <i>Head and Neck</i> , 2019 , 41, 835	4.2	1
346	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. <i>Journal of Experimental Medicine</i> , 2019 , 216, 419-427	16.6	34
345	Otogenic Pneumocephalus Presenting as Pneumatocele of the Scalp. <i>American Journal of Medicine</i> , 2019 , 132, 1170-1172	2.4	
344	Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage. <i>Cancer</i> , 2019 , 125, 3198-3207	6.4	16
343	Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1683-1685	2.2	4
342	The changing therapeutic landscape of head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 669-683	19.4	195
341	Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. <i>Cancer</i> , 2019 , 125, 2782-2793	6.4	19
340	Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. <i>Head and Neck</i> , 2019 , 41, 3056-3063	4.2	11
339	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. <i>Oncol Immunology</i> , 2019 , 8, 1593805	7.2	66
338	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019 , 41, 2591-2601	4.2	12
337	Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. <i>Oral Oncology</i> , 2019 , 91, 97-106	4.4	27
336	Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. <i>Head and Neck</i> , 2019 , 41, 1178-1183	4.2	5
335	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019 , 96, 140-147	4.4	21
334	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 2019 , 7, 184		223
333	Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response. <i>Cancers</i> , 2019 , 11,	6.6	6
332	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2019 , 95, 106-114	4.4	11
331	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019 , 96, 7-14	4.4	23
330	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019 , 25, 5221-5230	12.9	74

329	Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. <i>Frontiers in Oncology</i> , 2019 , 9, 464	5.3	28
328	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019 , 125, 3208-3218	6.4	44
327	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). <i>Frontiers in Oncology</i> , 2019 , 9, 1125	5.3	2
326	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). <i>Frontiers in Oncology</i> , 2019 , 9, 1126	5.3	2
325	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). <i>Frontiers in Oncology</i> , 2019 , 9, 1127	5.3	
324	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). <i>Frontiers in Oncology</i> , 2019 , 9, 1128	5.3	2
323	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , 2019 , 394, 1882-1884	4.0	5
322	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019 , 99, 104460	4.4	99
321	Dose-response modeling the risk of carotid bleeding events after stereotactic body radiation therapy for previously irradiated head and neck cancer. <i>Journal of Radiosurgery and SBRT</i> , 2019 , 6, 83-89 ^{0.4}		2
320	Hypopharyngeal cancer treatment: Does initial surgery confer survival benefit?. <i>Head and Neck</i> , 2019 , 41, 2167-2173	4.2	10
319	Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. <i>Radiotherapy and Oncology</i> , 2019 , 131, 192-201	5.3	6
318	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. <i>Journal of Virology</i> , 2019 , 93,	6.6	15
317	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , 2019 , 41, 843-856	4.2	7
316	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. <i>JAMA Oncology</i> , 2019 , 5, 204-212	13.4	171
315	Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic Radiosurgery. <i>Neurosurgery</i> , 2019 , 85, 632-641	3.2	16
314	Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. <i>Laryngoscope</i> , 2019 , 129, 162-169	3.6	33
313	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. <i>OncolImmunology</i> , 2018 , 7, e1442168	7.2	38
312	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV status in head and neck cancer. <i>Oral Oncology</i> , 2018 , 78, 186-193	4.4	25

311	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018 , 20, 22	6.3	75
310	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018 , 81, 45-51	4.4	372
309	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. <i>Cancer</i> , 2018 , 124, 1682-1690	6.4	180
308	Thyroidectomy in patients who have undergone gastric bypass surgery. <i>Head and Neck</i> , 2018 , 40, 1237-1244	4.4	9
307	Perineural Invasion in Parotid Gland Malignancies. <i>Otolaryngology - Head and Neck Surgery</i> , 2018 , 158, 1035-1041	5.5	26
306	Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 195-200	4	19
305	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018 , 77, 92-97	4.4	6
304	Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer. <i>International Journal of Cancer</i> , 2018 , 142, 2518-2528	7.5	12
303	Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018 , 24, 4529-4538	12.9	52
302	Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma. <i>Journal of Radiation Oncology</i> , 2018 , 7, 187-193	0.7	1
301	Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. <i>Head and Neck</i> , 2018 , 40, 1743-1751	4.2	4
300	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 595-605	4	63
299	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018 , 124, 84-94	6.4	12
298	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. <i>Clinical Cancer Research</i> , 2018 , 24, 62-72	12.9	39
297	Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy. <i>Radiotherapy and Oncology</i> , 2018 , 126, 100-106	5.3	13
296	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1583-1588	13.4	52
295	Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer. <i>Scientific Reports</i> , 2018 , 8, 10716	4.9	6
294	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018 , 124, 3586-3595	6.4	2

293	Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort. <i>Oral Oncology</i> , 2018 , 84, 82-87	4.4	13
292	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018 , 23, 1079-1082	5.7	44
291	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018 , 365-396	0.2	
290	Use of Intraoperative Indocyanine Green Endoscopy in the Assessment of Vascularity of Intranasal Flaps. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018 , 79, S1-S188	1.5	
289	Endonasal Suturing of Nasoseptal Flap to the Nasopharyngeal Fascia Using the V-Loc Wound Closing Device. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018 , 79, S1-S188	1.5	
288	Perineural Spread of Squamous Cell Carcinoma to the Skull Base Following Treatment of Oropharyngeal P16-Positive Squamous Cell Carcinoma: A Case Series. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018 , 79, S1-S188	1.5	
287	Role of Immunotherapy in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018 , 28, 12-16	5.5	47
286	Staged Reconstruction (Delayed-Immediate) of the Maxillectomy Defect Using CAD/CAM Technology. <i>Journal of Reconstructive Microsurgery</i> , 2018 , 34, 193-199	2.5	9
285	Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2018 , 158, 660-666	5.5	15
284	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018 , 63, 48-60	14.4	89
283	Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy. <i>Practical Radiation Oncology</i> , 2018 , 8, e125-e131	2.8	6
282	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3926-3940	15.9	88
281	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC) 2018 , 341-355		1
280	Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018 , 25, 2208-2222.e7	10.6	15
279	Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment. <i>Oral Oncology</i> , 2018 , 87, 170-176	4.4	17
278	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. <i>Onc Immunology</i> , 2018 , 7, e1494112	7.2	19
277	PD-L1 Mediates Dysfunction in Activated PD-1 NK Cells in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2018 , 6, 1548-1560	12.5	73
276	Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 68	5.4	13

275	The addition of chemotherapy in the definitive management of high risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 475-487	2.8	4
274	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. <i>Cell Reports</i> , 2018 , 25, 1332-1345.e5	10.6	42
273	Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group Position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study. <i>European Journal of Cancer</i> , 2018 , 103, 69-77	7.5	10
272	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. <i>PLoS ONE</i> , 2018 , 13, e0203402	3.7	16
271	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018 , 40, 1685-1690	4.2	20
270	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. <i>Clinical Cancer Research</i> , 2018 , 24, 4242-4255	12.9	63
269	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. <i>Head and Neck</i> , 2018 , 40, 1881-1888	4.2	29
268	Transoral robotic-assisted supracricoid partial laryngectomy with cricohyoidoepiglottomy: Procedure development and outcomes of initial cases. <i>Head and Neck</i> , 2018 , 40, 2254-2262	4.2	4
267	Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 382-388	3.9	21
266	Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically. <i>Oral Oncology</i> , 2017 , 65, 89-93	4.4	14
265	Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: A Prospective observational cohort study. <i>Head and Neck</i> , 2017 , 39, 965-973	4.2	15
264	Oncogenic growth factor signaling mediating tumor escape from cellular immunity. <i>Current Opinion in Immunology</i> , 2017 , 45, 52-59	7.8	11
263	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 490-497	2.2	273
262	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. <i>Head and Neck</i> , 2017 , 39, 840-852	4.2	27
261	Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status. <i>Oral Oncology</i> , 2017 , 66, 9-13	4.4	38
260	Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. <i>Oral Oncology</i> , 2017 , 67, 146-152	4.4	81
259	Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 542-548	3.9	23
258	fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 2307-2312	11.5	34

257	Increased PD-1 and TIM-3 TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 408-416	12.5	58
256	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1405-1410	4.4	14
255	A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2017 , 123, 3132-3140	6.4	25
254	Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 806-812	4	19
253	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017 , 22, 680-693	5.7	22
252	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. <i>Oncolmmunology</i> , 2017 , 6, e1329071	7.2	62
251	Interferon- γ Drives T Fragility to Promote Anti-tumor Immunity. <i>Cell</i> , 2017 , 169, 1130-1141.e11	56.2	261
250	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017 , 76, 152-166	7.5	62
249	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 483-491	13.4	37
248	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. <i>Oncolmmunology</i> , 2017 , 6, e1261779	7.2	152
247	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , 2017 , 15, 179-188	6.6	14
246	Defining the Prevalence and Prognostic Value of Perineural Invasion and Angiolymphatic Invasion in Human Papillomavirus-Positive Oropharyngeal Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 1236-1243	3.9	11
245	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017 , 39, 2433-2443	4.2	4
244	Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017 , 123, 4382-4390	6.4	51
243	PD-1 Status in CD8 T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. <i>Cancer Research</i> , 2017 , 77, 6353-6364	10.1	111
242	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017 , 73, 138-146	4.4	61
241	National evaluation of multidisciplinary quality metrics for head and neck cancer. <i>Cancer</i> , 2017 , 123, 4376-4381	7.4	137
240	Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. <i>Oral Oncology</i> , 2017 , 75, 184-188	4.4	13

239	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1104-1115	21.7	232
238	Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities. <i>Practical Radiation Oncology</i> , 2017 , 7, e419-e425	2.8	9
237	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 707-716	12.9	74
236	Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction: A Consensus Review and Recommendations From the Enhanced Recovery After Surgery Society. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 292-303	3.9	218
235	Management of Pharyngeal Fistulas After Anterior Cervical Spine Surgery: A Treatment Algorithm for Severe Complications. <i>Clinical Spine Surgery</i> , 2017 , 30, E25-E30	1.8	4
234	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. <i>Frontiers in Pharmacology</i> , 2017 , 8, 382	5.6	21
233	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	122
232	Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. <i>Frontiers in Pharmacology</i> , 2017 , 8, 332	5.6	18
231	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017 , 2, e90449	9.9	30
230	Evaluation of Intranasal Flap Perfusion by Intraoperative ICG Fluorescence Angiography. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017 , 78, S1-S156	1.5	
229	Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. <i>Head and Neck</i> , 2017 , 39, 1510-1515	4.2	35
228	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. <i>Annual Review of Medicine</i> , 2016 , 67, 91-101	17.4	73
227	Analysis of post-transoral robotic-assisted surgery hemorrhage: Frequency, outcomes, and prevention. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E776-82	4.2	69
226	Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016 , 60, 55-60	4.4	15
225	Risk factors for radiation failure in early-stage glottic carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2016 , 62, 90-100	4.4	31
224	Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2016 , 62, 60-71	4.4	110
223	Factors Influencing the Incidence of Severe Complications in Head and Neck Free Flap Reconstructions. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016 , 4, e1013	1.2	13
222	Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1613-7	4.2	12

221	Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 973-980	4	39
220	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. <i>Oral Oncology</i> , 2016 , 58, 52-8	4.4	37
219	Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. <i>Cancer</i> , 2016 , 122, 2021-30	6.4	20
218	Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E494-501	4.2	10
217	Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E2143-50	4.2	38
216	Utility of a perioperative nutritional intervention on postoperative outcomes in high-risk head & neck cancer patients. <i>Oral Oncology</i> , 2016 , 54, 42-6	4.4	22
215	Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2016 , 37, 522-9	4.6	38
214	Utility of Diagnostic Molecular Markers for Evaluation of Indeterminate Thyroid Nodules. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 421-2	3.9	7
213	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. <i>Journal of Immunology</i> , 2016 , 196, 2870-8	5.3	16
212	Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. <i>Cancer Immunology Research</i> , 2016 , 4, 441-51	12.5	21
211	A 20-Year Review of 75 Cases of Salivary Duct Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 489-95	3.9	84
210	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. <i>Cancer Research</i> , 2016 , 76, 1031-43	10.1	193
209	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. <i>American Journal of Medicine</i> , 2016 , 129, e29-31	2.4	2
208	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6009-6009	2.2	27
207	Utility of up-front transoral robotic surgery in tailoring adjuvant therapy. <i>Head and Neck</i> , 2016 , 38, 1201-7.	4.2	25
206	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016 , 38, 493-8	4.2	46
205	Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38, 1467-71	4.2	20
204	Transthyrohyoid access to the larynx for endoscopic resection of early-stage glottic cancer. <i>Head and Neck</i> , 2016 , 38, 1286-9	4.2	2

203	Current Role of Surgery in the Management of Oropharyngeal Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, 1176-1183	3.1	15
202	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 5229-5237	12.9	85
201	Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. <i>Oral Oncology</i> , 2016 , 53, 60-6	4.4	7
200	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. <i>Cancer Epidemiology</i> , 2016 , 42, 46-52	2.8	28
199	Is There a Role for Robotic Surgery in the Treatment of Head and Neck Cancer?. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 29	5.4	20
198	Immunology of Head and Neck Cancer 2016 , 133-148		
197	Tumor-infiltrating Tim-3 T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. <i>Oncot Immunology</i> , 2016 , 5, e1200778	7.2	34
196	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. <i>Cancers of the Head & Neck</i> , 2016 , 1, 12	5.9	13
195	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2	2647
194	The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. <i>Immunity</i> , 2016 , 45, 374-88	32.3	312
193	Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. <i>Cancer</i> , 2016 , 122, 3136-3144	6.4	54
192	Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 1104-10	3.9	69
191	STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2103-11	6.1	13
190	Immune Escape and Immunotherapy of HPV-Related Oropharyngeal Cancer: Has the Future Arrived?. <i>Current Otorhinolaryngology Reports</i> , 2015 , 3, 63-72	0.5	
189	Cancer of the oropharynx. <i>Surgical Oncology Clinics of North America</i> , 2015 , 24, 509-20	2.7	10
188	Accuracy of early-phase versus dual-phase single-photon emission computed tomography/computed tomography in the localization of parathyroid disease. <i>Laryngoscope</i> , 2015 , 125, 1496-501	3.6	11
187	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015 , 75, 2200-10	10.1	175
186	Oncologic Outcomes After Transoral Robotic Surgery: A Multi-institutional Study. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 1043-1051	3.9	191

185	Immunology and Immunotherapy of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3293-304	3.04	381
184	Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3285-92	2.2	117
183	Overview of Advances in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3225-6	2.2	27
182	Congenital lobar emphysema presenting as an airway foreign body. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015 , 79, 2450-2	1.7	4
181	PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. <i>Cancer Research</i> , 2015 , 75, 508-518	10.1	133
180	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. <i>BMC Cancer</i> , 2015 , 15, 861	4.8	26
179	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients 2015 , 3, 54		30
178	Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners. <i>Head and Neck</i> , 2015 , 37, 1282-9	4.2	38
177	Accuracy of computed tomography to predict extracapsular spread in p16-positive squamous cell carcinoma. <i>Laryngoscope</i> , 2015 , 125, 1613-8	3.6	39
176	Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. <i>Annals of Surgery</i> , 2015 , 262, 519-25; discussion 524-5	7.8	69
175	Response to Letter to the Editor on COI for American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules. <i>Thyroid</i> , 2015 , 25, 1266	6.2	1
174	Transoral robotic surgery alone for oropharyngeal cancer: quality-of-life outcomes. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 499-504	3.9	56
173	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. <i>Cancer Immunology Research</i> , 2015 , 3, 936-45	12.5	54
172	American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. <i>Thyroid</i> , 2015 , 25, 760-8	6.2	157
171	Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy. <i>Frontiers in Oncology</i> , 2015 , 5, 65	5.3	6
170	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. <i>Thyroid</i> , 2015 , 25, 1217-23	6.2	282
169	Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind. <i>JAMA Oncology</i> , 2015 , 1, 915-7	13.4	2
168	A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 480-8	4	81

167	Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. <i>Cancer Prevention Research</i> , 2015 , 8, 197-207	3.2	41
166	Surgical trials in head and neck oncology: Renaissance and revolution?. <i>Head and Neck</i> , 2015 , 37, 927-30	4.2	9
165	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015 , 75, 2200-2210	10.1	114
164	Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. <i>Head and Neck</i> , 2014 , 36, 1349-55	4.2	31
163	Combination antiangiogenic therapy and radiation in head and neck cancers. <i>Oral Oncology</i> , 2014 , 50, 19-26	4.4	70
162	Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions. <i>Otolaryngology - Head and Neck Surgery</i> , 2014 , 151, 272-8	5.5	41
161	Adjuvant stereotactic body radiotherapy+ cetuximab following salvage surgery in previously irradiated head and neck cancer. <i>Laryngoscope</i> , 2014 , 124, 1579-84	3.6	16
160	Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. <i>Laryngoscope</i> , 2014 , 124, 1592-7	3.6	47
159	Multi-institutional investigation of the prognostic value of lymph node yield in advanced-stage oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2014 , 36, 1446-52	4.2	20
158	Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. <i>Seminars in Oncology</i> , 2014 , 41, 678-84	5.5	13
157	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. <i>Cancer</i> , 2014 , 120, 3627-34	6.4	379
156	Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. <i>Journal of Immunology</i> , 2014 , 193, 1525-30	5.3	111
155	Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. <i>Otolaryngologic Clinics of North America</i> , 2014 , 47, 557-71	2	11
154	Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 4233-8	11.5	191
153	Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history. <i>Oral Oncology</i> , 2014 , 50, 1104-8	4.4	18
152	Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3289-98	12.9	36
151	Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2014 , 150, 976-82	5.5	40
150	Tailored immunotherapy for HPV positive head and neck squamous cell cancer. <i>Oral Oncology</i> , 2014 , 50, 780-4	4.4	24

149	Use of combined suspension laryngoscopy and jet ventilation for Y-shaped airway stents delivery. <i>Annals of Thoracic Surgery</i> , 2014 , 97, 2208-10	2.7	5
148	Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) 2014 , 2, P69		78
147	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, 603-10	3.1	45
146	Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. <i>PLoS ONE</i> , 2014 , 9, e102452	3.7	22
145	Acute neurorehabilitation: does a neurosensory and coordinated interdisciplinary programme reduce tracheostomy weaning time and weaning failure?. <i>NeuroRehabilitation</i> , 2014 , 34, 809-17	2	11
144	Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 214	5.3	28
143	Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. <i>Head and Neck</i> , 2014 , 36, 511-6	4.2	59
142	Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope</i> , 2014 , 124, 1843-7	3.6	37
141	Phase I dendritic cell p53 peptide vaccine for head and neck cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2433-44	12.9	95
140	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. <i>Cancer</i> , 2014 , 120, 624-32	6.4	39
139	Large-scale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies. <i>Frontiers in Immunology</i> , 2014 , 5, 38	8.4	11
138	Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. <i>Oral Oncology</i> , 2014 , 50, 662-9	4.4	8
137	Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6033-6033	2.2	5
136	Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6090-6090	2.2	4
135	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6006-LBA6006	2.2	6
134	Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS6104-TPS6104	2.2	0
133	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA6006-LBA6006	2.2	21
132	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6086-6086	2.2	

131	Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3123-TPS3123	2.2	
130	Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6035-6035	2.2	
129	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. <i>Cancer</i> , 2013 , 119, 3034-42	6.4	138
128	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013 , 49, 1089-96	4.4	85
127	Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed. <i>Oral Oncology</i> , 2013 , 49, 1077-82	4.4	49
126	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2013 , 13, 602	4.8	45
125	Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. <i>Cancer</i> , 2013 , 119, 3302-8	6.4	143
124	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. <i>Cancer Discovery</i> , 2013 , 3, 761-9	24.4	414
123	A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery. <i>Laryngoscope</i> , 2013 , 123, 146-51	3.6	110
122	Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2013 , 49, 591-7	4.4	8
121	Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. <i>Radiotherapy and Oncology</i> , 2013 , 106, 90-5	5.3	33
120	Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. <i>Oral Oncology</i> , 2013 , 49, 401-6	4.4	18
119	Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. <i>Head and Neck</i> , 2013 , 35, 1499-506	4.2	17
118	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013 , 45, 791-8	36.3	311
117	TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1347-57	7.4	55
116	RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E914-22	5.6	110
115	Diagnosis and management of differentiated thyroid cancer using molecular biology. <i>Laryngoscope</i> , 2013 , 123, 1059-64	3.6	42
114	Accuracy of computed tomography in the prediction of extracapsular spread of lymph node metastases in squamous cell carcinoma of the head and neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013 , 139, 1187-94	3.9	65

113	The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. <i>Clinical Cancer Research</i> , 2013 , 19, 889-99	12.9	45
112	Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1586-91	6.7	39
111	EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. <i>Oncolmmunology</i> , 2013 , 2, e27215	7.2	27
110	SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. <i>Clinical Cancer Research</i> , 2013 , 19, 798-808	12.9	58
109	TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. <i>Oncolmmunology</i> , 2013 , 2, e24677	7.2	39
108	Oncologic and functional outcomes of partial laryngeal surgery for intermediate-stage laryngeal cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2013 , 148, 235-42	5.5	24
107	Correlation of tumor marker expression with nodal disease burden in metastatic head and neck cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2013 , 149, 261-8	5.5	13
106	Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. <i>Clinical Cancer Research</i> , 2013 , 19, 1858-72	12.9	222
105	E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6005-6005	2.2	15
104	In regard to "ACR appropriateness criteria of recurrent head-and-neck cancer after prior definitive radiation." (Int J Radiat Oncol Biol Phys 2011;80:1292-1298). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1322-3; author reply 1315-6	4	1
103	Re-irradiation strategies for head-and-neck cancers: implications for stereotactic body radiotherapy: in regard to Chen et al (Int J Radiat Oncol Biol Phys 2011;81:1211-1219). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 769-70	4	
102	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 729-36	4.7	30
101	Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer. <i>Radiotherapy and Oncology</i> , 2012 , 104, 91-5	5.3	39
100	Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. <i>Head and Neck</i> , 2012 , 34, 1681-703	4.2	77
99	Prevention and management of dysphonia during anterior cervical spine surgery. <i>Laryngoscope</i> , 2012 , 122, 2179-83	3.6	12
98	A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer. <i>Head & Neck Oncology</i> , 2012 , 4, 12		18
97	Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. <i>Oral Oncology</i> , 2012 , 48, 1136-45	4.4	11
96	Sentinel lymph node biopsy versus selective neck dissection for detection of metastatic oral squamous cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 693-8	4.7	9

95	American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. <i>Thyroid</i> , 2012 , 22, 501-8	6.2	184
94	Rapid molecular detection of metastatic head and neck squamous cell carcinoma as an intraoperative adjunct to sentinel lymph node biopsy. <i>Laryngoscope</i> , 2012 , 122, 1020-30	3.6	25
93	Molecular biology of adenoid cystic carcinoma. <i>Head and Neck</i> , 2012 , 34, 1665-77	4.2	55
92	Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. <i>Head and Neck</i> , 2012 , 34, 1153-61	4.2	30
91	A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. <i>Cancer</i> , 2012 , 118, 2069-77	6.4	107
90	First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. <i>Cancer Discovery</i> , 2012 , 2, 694-705	24.4	214
89	The role of cetuximab in the management of head and neck cancers. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 517-28	5.4	16
88	Defective NF- κ B signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. <i>Cancer Research</i> , 2012 , 72, 45-55	10.1	27
87	Chemokine receptor 7 (CCR7) gene expression is regulated by NF- κ B and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). <i>Journal of Biological Chemistry</i> , 2012 , 287, 3581-90	5.4	42
86	The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 372-9	2.7	77
85	The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. <i>JAMA Otolaryngology</i> , 2011 , 137, 1106-11		24
84	Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 165-72	2.7	83
83	Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 478-82	2.7	19
82	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2011 , 47, 961-6	4.4	42
81	The central repeat domain 1 of Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation. <i>Virology</i> , 2011 , 412, 357-65	3.6	34
80	Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 525-35	7.4	71
79	Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. <i>Immunologic Research</i> , 2011 , 50, 248-54	4.3	116
78	EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2011 , 9, 168	8.5	11

77	Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. <i>Journal of Surgical Oncology</i> , 2011 , 103, 518-30	2.8	28
76	Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies. <i>Head and Neck</i> , 2011 , 33, 225-231	4.2	34
75	Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. <i>Head and Neck</i> , 2011 , 33, 318-23	4.2	26
74	Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. <i>Head and Neck</i> , 2011 , 33, 504-12	4.2	116
73	Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. <i>Clinical Cancer Research</i> , 2011 , 17, 6174-84	12.9	135
72	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3390-7	5.6	614
71	Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1858-66	12.9	48
70	Human β -defensin 3 promotes NF- κ B-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. <i>Carcinogenesis</i> , 2011 , 32, 168-74	4.6	35
69	Immunology of Head and Neck Cancer 2011 , 107-119		1
68	Lipid accumulation and dendritic cell dysfunction in cancer. <i>Nature Medicine</i> , 2010 , 16, 880-6	50.5	386
67	Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4390-9	2.2	243
66	Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1395-400	2.2	265
65	Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5294-300	2.2	116
64	Community members as recruiters of human subjects: ethical considerations. <i>American Journal of Bioethics</i> , 2010 , 10, 3-11	1.1	56
63	Response to open peer commentaries on "Community members as recruiters of human subjects: ethical considerations". <i>American Journal of Bioethics</i> , 2010 , 10, W1-3	1.1	2
62	Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. <i>Radiotherapy and Oncology</i> , 2010 , 97, 395-8	5.3	34
61	Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. <i>Laryngoscope</i> , 2010 , 120, 71-5	3.6	30
60	Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. <i>Journal of Immunotherapy</i> , 2010 , 33, 83-91	5	29

59	Response to the letter to the editors by Ottaiano et al.: Cetuximab-dependent ADCC in cancer: dream or reality? <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1609-1610	7.4	
58	CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1561-8	7.4	10
57	Current concepts and new horizons in conservation laryngeal surgery: an important part of multidisciplinary care. <i>Head and Neck</i> , 2010 , 32, 656-65	4.2	19
56	Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2010 , 32, 1412-21	4.2	95
55	Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. <i>Laryngoscope</i> , 2010 , 120, 734-8	3.6	48
54	PET-CT staging of the neck in cancers of the oropharynx: patterns of regional and retropharyngeal nodal metastasis. <i>World Journal of Surgical Oncology</i> , 2010 , 8, 70	3.4	19
53	Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 286-93	2.7	68
52	HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3740-50	12.9	177
51	Immunotherapy for head and neck cancer. <i>Oral Oncology</i> , 2009 , 45, 747-51	4.4	7
50	Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. <i>International Journal of Cancer</i> , 2009 , 125, 1912-20	7.5	26
49	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. <i>Current Oncology Reports</i> , 2009 , 11, 156-62	6.3	17
48	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1853-64	7.4	139
47	Lack of toxicity of a STAT3 decoy oligonucleotide. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 983-95	3.5	44
46	Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. <i>Journal of Immunotherapy</i> , 2009 , 32, 465-73	5	33
45	Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. <i>Laryngoscope</i> , 2008 , 118, 2129-34	3.6	59
44	Head and neck cancer. <i>Lancet, The</i> , 2008 , 371, 1695-709	4.0	1323
43	Reoperative parathyroidectomy. <i>Otolaryngologic Clinics of North America</i> , 2008 , 41, 1269-74, xii	2	24
42	Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 502-12	9.7	62

41	Head and neck cancer immunotherapy: clinical evaluation. <i>Current Oncology Reports</i> , 2008 , 10, 162-9	6.3	15
40	Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. <i>Proteomics - Clinical Applications</i> , 2008 , 2, 1575-1585	3.1	35
39	Minimally invasive video-assisted thyroidectomy: expanded indications and oncologic completeness. <i>Head and Neck</i> , 2008 , 30, 1403-7	4.2	36
38	STAT3 and immune escape in head and neck squamous cell carcinoma. <i>FASEB Journal</i> , 2008 , 22, 1078.23	0.9	
37	Autocrine CCR7 signaling is mediated by NF-kappaB in SCCHN. <i>FASEB Journal</i> , 2008 , 22, 1070.32	0.9	
36	CD8+ T cell Recognition of Polymorphic Wild Type Sequence p536573 Peptides in Squamous Cell Carcinoma of the Head and Neck. <i>FASEB Journal</i> , 2008 , 22, 1079.15	0.9	
35	Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. <i>FASEB Journal</i> , 2008 , 22, 1068.22	0.9	
34	Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. <i>Head and Neck</i> , 2007 , 29, 163-88	4.2	180
33	Head and neck squamous and thyroid carcinomas: multiplexed Luminex approaches for early detection. <i>Expert Opinion on Medical Diagnostics</i> , 2007 , 1, 129-36		3
32	Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 102-7	4	96
31	NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 5663-4	12.9	22
30	Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. <i>JAMA Otolaryngology</i> , 2007 , 133, 1277-81		74
29	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3890-5	12.9	174
28	Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2006 , 12, 2394-403	12.9	21
27	Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. <i>Journal of Immunology</i> , 2006 , 176, 3402-9	5.3	127
26	CCR7 mediates inflammation-associated tumor progression. <i>Immunologic Research</i> , 2006 , 36, 61-72	4.3	44
25	Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2006 , 263, 313-8	3.5	18
24	Exploring websites on cancer clinical trials: an empirical review. <i>Contemporary Clinical Trials</i> , 2005 , 26, 530-3	2.3	10

23	Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. <i>Clinical Immunology</i> , 2005 , 116, 27-36	9	25
22	Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. <i>European Journal of Cancer</i> , 2005 , 41, 807-15	7.5	79
21	Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. <i>Immunologic Research</i> , 2005 , 33, 113-33	4.3	84
20	Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. <i>Laryngoscope</i> , 2005 , 115, 522-7	3.6	42
19	Diagnostic utility of positron emission tomography-computed tomography for predicting malignancy in cystic neck masses in adults. <i>Laryngoscope</i> , 2005 , 115, 1979-82	3.6	17
18	Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 1072-81	7.4	90
17	Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. <i>Clinical Cancer Research</i> , 2005 , 11, 7901-10	12.9	57
16	Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. <i>Cancer Research</i> , 2005 , 65, 2147-56	10.1	94
15	Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. <i>Cancer Research</i> , 2005 , 65, 11146-55	10.1	126
14	Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2004 , 10, 3755-62	12.9	192
13	Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?. <i>Orl</i> , 2004 , 66, 332-40	2	25
12	Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. <i>Cancer Research</i> , 2004 , 64, 1861-6	10.1	134
11	Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2004 , 10, 6929-37	12.9	32
10	Elective neck dissection and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx. <i>Laryngoscope</i> , 2004 , 114, 2228-34	3.6	80
9	Molecular biology of primary hyperparathyroidism. <i>Otolaryngologic Clinics of North America</i> , 2004 , 37, 819-31, x	2	11
8	Steroid psychosis after head and neck surgery: case report and review of the literature. <i>Otolaryngology - Head and Neck Surgery</i> , 2003 , 129, 591-2	5.5	8
7	Diagnostic assessment of laryngeal cancer. <i>Otolaryngologic Clinics of North America</i> , 2002 , 35, 953-69, v	2	22
6	Functional laryngeal dyskinesia in children and adults. <i>Laryngoscope</i> , 1998 , 108, 1520-3	3.6	13

5	An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. <i>Laryngoscope</i> , 1998 , 108, 1686-91	3.6	31
4	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines23-43		3
3	Expression of Tim-3 drives naïve Treg to an effector-like state with enhanced suppressive activity		1
2	Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8+ T cells		2
1	Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures		1